ELMO, a new helmet interface for CPAP to treat COVID-19-related acute hypoxemic respiratory failure outside the ICU: a feasibility study.
Betina Santos TomazGabriela Carvalho GomesJuliana Arcanjo LinoDavid Guabiraba Abitbol de MenezesJorge Barbosa SoaresVasco FurtadoLuiz Soares JúniorMaria do Socorro Quintino FariasDebora Lilian Nascimento LimaEanes Delgado Barros PereiraMarcelo Alcantara HolandaPublished in: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2022)
The use of ELMOcpap has proven to be feasible and effective in delivering high-flow CPAP to patients with COVID-19-related AHRF outside the ICU. There were no major adverse effects, and ELMO was considered comfortable. ELMOcpap sessions significantly improved oxygenation, reducing FIO2 without CO2 rebreathing. The overall success rate was 60% in this pilot study, and further clinical trials should be carried out in the future.(ClinicalTrials.gov identifier: NCT04470258 [http://www.clinicaltrials.gov/]).